191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

Publication | Open Access

DOI Full Paper Access

Citations

References

2016

Year

Solange Peters, Scott Antonia, Sarah B. Goldberg, John V. Heymach, Erin Kim, Kazuhiko Nakagawa, V. Papadimitrakopoulou, P. Mukhopadhyay, Stuart McIntosh, Naiyer A. Rizvi

Journal of Thoracic Oncology

Durvalumab MonotherapyCancer TherapeuticsMedicineClinical TrialsTremelimumab Combination TherapyImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentLung CancerRadiation OncologyOncologyCancer ChemotherapyChemotherapyPlatinum-based ChemotherapyHealth Sciences